Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],576,11429,DB00370,Mirtazapine
,12242602,AUC(0-24),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[h·ng] / [ml],305,11430,DB00370,Mirtazapine
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],69.7,11431,DB00370,Mirtazapine
,12242602,C(max),The addition of phenytoin to an existing daily administration of mirtazapine resulted in a mean (+/-SD) decrease of the AUC(0-24) from 576+/-104 ng h/ml to 305+/-81.6 ng h/ml and a mean decrease of C(max) from 69.7+/-17.5 ng/ml to 46.9+/-10.9 ng/ml.,Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242602/),[ng] / [ml],46.9,11432,DB00370,Mirtazapine
,30307637,time to maximum serum concentration,There was a significant difference in time to maximum serum concentration between LD cats and control cats (median [range]: 4 [1-4] hours versus 1 [1-4] hours; P = .03).,In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307637/),h,4,14058,DB00370,Mirtazapine
,30307637,time to maximum serum concentration,There was a significant difference in time to maximum serum concentration between LD cats and control cats (median [range]: 4 [1-4] hours versus 1 [1-4] hours; P = .03).,In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307637/),h,1,14059,DB00370,Mirtazapine
,30307637,half-life,The calculated half-life of LD cats was significantly prolonged compared to controls (median [range]: 13.8 [7.9-61.4] hours versus 7.4 [6.7-9.1] hours; P < .002).,In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307637/),h,13.8,14060,DB00370,Mirtazapine
,30307637,half-life,The calculated half-life of LD cats was significantly prolonged compared to controls (median [range]: 13.8 [7.9-61.4] hours versus 7.4 [6.7-9.1] hours; P < .002).,In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307637/),h,7.4,14061,DB00370,Mirtazapine
,30307637,rate of loss,"The rate of loss of mirtazapine was significantly different between microsomes of LD cats (-0.0022 min-1 , CI: -0.0050 to 0.00054 min-1 ) and cats without LD (0.01849 min-1 , CI: -0.025 to -0.012 min-1 ; P = .002).",In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30307637/),1/[min],0.01849,14062,DB00370,Mirtazapine
,22139691,encapsulation efficiency,The encapsulation efficiency of different formulation varied from 53 ± 1.2% to 78 ± 1.5%.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),%,53,26542,DB00370,Mirtazapine
,22139691,encapsulation efficiency,The encapsulation efficiency of different formulation varied from 53 ± 1.2% to 78 ± 1.5%.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),%,78,26543,DB00370,Mirtazapine
,22139691,particle size,The mean particle size of the optimized formulation F-14 was 106.4 ± 0.5 μm.,Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),μm,106.4,26544,DB00370,Mirtazapine
,22139691,AUC,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),[h·μg] / [ml],177.70,26545,DB00370,Mirtazapine
,22139691,half-life,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),h,4.72,26546,DB00370,Mirtazapine
,22139691,clearance,"Pharmacokinetic studies revealed that the optimized formulation showed significant increases in systemic exposure (AUC = 177.70 ± 7.39 μg·h/mL), half-life (4.72 ± 0.46 h) and reduced clearance (0.009 ± 0.0001 L/h) compared to pure drug administration.",Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139691/),[l] / [h],0.009,26547,DB00370,Mirtazapine
,24397986,oral bioavailability,The oral bioavailability was about 7% in both groups.,Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24397986/),%,7,46737,DB00370,Mirtazapine
,22541842,C(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[ng] / [ml],58.715,61941,DB00370,Mirtazapine
,22541842,C(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[ng] / [ml],58.255,61942,DB00370,Mirtazapine
,22541842,AUC(0-t),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],591.406,61943,DB00370,Mirtazapine
,22541842,AUC(0-t),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],596.339,61944,DB00370,Mirtazapine
,22541842,AUC(0-∞),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],627.03,61945,DB00370,Mirtazapine
,22541842,AUC(0-∞),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),[h·ng] / [ml],631.521,61946,DB00370,Mirtazapine
,22541842,t(1/2),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,18.941,61947,DB00370,Mirtazapine
,22541842,t(1/2),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,18.285,61948,DB00370,Mirtazapine
,22541842,t(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,1.417,61949,DB00370,Mirtazapine
,22541842,t(max),"The main PK parameters of the mirtazapine test and reference tables were as follows: mean (SD) C(max), 58.715 (23.89) and 58.255 (22.34) ng/ml; AUC(0-t), 591.406 (186.79) and 596.339 (201.25) ng × h/ml; AUC(0-∞), 627.03 (201.39) and 631.521 (227.32) ng × h/ml; t(1/2), 18.941 (4.79) and 18.285 (3.91) h; t(max) 1.417 (0.61) and 1.424 (0.75) h.",Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22541842/),h,1.424,61950,DB00370,Mirtazapine
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],20.1,77476,DB00370,Mirtazapine
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],39.7,77477,DB00370,Mirtazapine
,15538128,total clearance of racemic mirtazapine (Cl/F),"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[l] / [h],49.8,77478,DB00370,Mirtazapine
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],129,77479,DB00370,Mirtazapine
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],159,77480,DB00370,Mirtazapine
,15538128,maximum plasma concentrations,"Median total clearance of racemic mirtazapine (Cl/F) was 20.1, 39.7, and 49.8 L/h in carriers of 0, 2, and 3 active genes of CYP2D6 (P = 0.002, trend test) and the median maximum plasma concentrations were 129, 159, and 76 mug/L in these 3 groups.",Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538128/),[μg] / [l],76,77481,DB00370,Mirtazapine
,17329996,rate constant,"Mirtazapine was enantioselectively absorbed from the gut with a rate constant of 0.2 min-1 for S+, but 0.08 min-1 for R- mirtazapine.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),1/[min],0.2,98098,DB00370,Mirtazapine
,17329996,rate constant,"Mirtazapine was enantioselectively absorbed from the gut with a rate constant of 0.2 min-1 for S+, but 0.08 min-1 for R- mirtazapine.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),1/[min],0.08,98099,DB00370,Mirtazapine
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],1.3,98100,DB00370,Mirtazapine
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],2.3,98101,DB00370,Mirtazapine
,17329996,total clearance,"Kinetics of R- mirtazapine was only marginally dependent on CYP2D6 genotype, but total clearance of the S+ enantiomer were 1.3, 2.3, and 3.4 L min-1 in poor, extensive, and ultrarapid metabolizers of CYP2D6 substrates with apparent substantial first-pass metabolism in rapid and ultrarapid metabolizers.",Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17329996/),[l] / [min],3.4,98102,DB00370,Mirtazapine
,22345050,run time,"Chromatography was performed isocratically on a C(18), 5 µm analytical column and the run time was 1.8 min.","A fast, sensitive and simple method for mirtazapine quantification in human plasma by HPLC-ESI-MS/MS. Application to a comparative bioavailability study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345050/),min,1.8,115889,DB00370,Mirtazapine
,20969604,half-life,Median half-life was 15.9 h (HD) and 9.2 h (LD).,Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20969604/),h,15.9,117645,DB00370,Mirtazapine
,20969604,half-life,Median half-life was 15.9 h (HD) and 9.2 h (LD).,Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20969604/),h,9.2,117646,DB00370,Mirtazapine
,9034228,elimination half-lives,"The observed elimination half-lives of 19.7 +/- 3.0 h and 20.8 +/- 2.7 h (n = 20) for NOCTE and BID, respectively are in agreement with previous results.",Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034228/),h,19.7,131223,DB00370,Mirtazapine
,9034228,elimination half-lives,"The observed elimination half-lives of 19.7 +/- 3.0 h and 20.8 +/- 2.7 h (n = 20) for NOCTE and BID, respectively are in agreement with previous results.",Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9034228/),h,20.8,131224,DB00370,Mirtazapine
,30004120,Tmax,"In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0-24 = 100 ng*hr/mL, AUC0-∞ = 260 ng*hr/mL and calculated half-life = 26.8 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,15.9,139425,DB00370,Mirtazapine
,30004120,Cmax,"In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0-24 = 100 ng*hr/mL, AUC0-∞ = 260 ng*hr/mL and calculated half-life = 26.8 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[ng] / [ml],21.5,139426,DB00370,Mirtazapine
,30004120,AUC0-24,"In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0-24 = 100 ng*hr/mL, AUC0-∞ = 260 ng*hr/mL and calculated half-life = 26.8 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],100,139427,DB00370,Mirtazapine
,30004120,AUC0-∞,"In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0-24 = 100 ng*hr/mL, AUC0-∞ = 260 ng*hr/mL and calculated half-life = 26.8 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],260,139428,DB00370,Mirtazapine
,30004120,half-life,"In Study 1, single transdermal administration of mirtazapine resulted in mean Tmax = 15.9 hr, Cmax = 21.5 ng/mL, AUC0-24 = 100 ng*hr/mL, AUC0-∞ = 260 ng*hr/mL and calculated half-life = 26.8 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,26.8,139429,DB00370,Mirtazapine
,30004120,Tmax,"Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0-24 = 377 ng*hr/mL, AUC0-∞ = 434 ng*hr/mL and calculated half-life = 10.1 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,1.1,139430,DB00370,Mirtazapine
,30004120,Cmax,"Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0-24 = 377 ng*hr/mL, AUC0-∞ = 434 ng*hr/mL and calculated half-life = 10.1 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[ng] / [ml],83.1,139431,DB00370,Mirtazapine
,30004120,AUC0-24,"Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0-24 = 377 ng*hr/mL, AUC0-∞ = 434 ng*hr/mL and calculated half-life = 10.1 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],377,139432,DB00370,Mirtazapine
,30004120,AUC0-∞,"Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0-24 = 377 ng*hr/mL, AUC0-∞ = 434 ng*hr/mL and calculated half-life = 10.1 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],434,139433,DB00370,Mirtazapine
,30004120,half-life,"Single oral administration of mirtazapine resulted in mean Tmax = 1.1 hr, Cmax = 83.1 ng/mL, AUC0-24 = 377 ng*hr/mL, AUC0-∞ = 434 ng*hr/mL and calculated half-life = 10.1 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,10.1,139434,DB00370,Mirtazapine
,30004120,relative bioavailability (F),Mean relative bioavailability (F) of transdermal to oral dosing was 64.9%.,Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),%,64.9,139435,DB00370,Mirtazapine
,30004120,Tmax,"In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0-24 = 400 ng*hr/mL, AUC0-∞ = 647 ng*hr/mL and calculated half-life = 20.7 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,2.1,139436,DB00370,Mirtazapine
,30004120,Cmax,"In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0-24 = 400 ng*hr/mL, AUC0-∞ = 647 ng*hr/mL and calculated half-life = 20.7 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[ng] / [ml],39.6,139437,DB00370,Mirtazapine
,30004120,AUC0-24,"In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0-24 = 400 ng*hr/mL, AUC0-∞ = 647 ng*hr/mL and calculated half-life = 20.7 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],400,139438,DB00370,Mirtazapine
,30004120,AUC0-∞,"In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0-24 = 400 ng*hr/mL, AUC0-∞ = 647 ng*hr/mL and calculated half-life = 20.7 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),[h·ng] / [ml],647,139439,DB00370,Mirtazapine
,30004120,half-life,"In Study 2, daily application of mirtazapine for 14 days resulted in mean Tmax = 2.1 hr, Cmax = 39.6 ng/mL, AUC0-24 = 400 ng*hr/mL, AUC0-∞ = 647 ng*hr/mL and calculated half-life = 20.7 hr.",Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30004120/),h,20.7,139440,DB00370,Mirtazapine
,28547577,concentration,"The initial plasma pramipexole concentration was 34.2 ng/mL (therapeutic range 0.2 to 7 ng/mL), 9 h post-overdose.","Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),[ng] / [ml],34.2,162674,DB00370,Mirtazapine
,28547577,elimination half-life,Concentration time data fitted a one-compartment model with an estimated elimination half-life of 18 h.,"Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28547577/),h,18,162675,DB00370,Mirtazapine
,15315787,flow rate,"The chromatographic separation of the (+)-(S)- and (-)-(R)-enantiomers of mirtazapine was achieved on a Chiralpak AD column (250 mm x 4.6 mm, 10 microm particle size) protected with a CN guard column, using hexane-ethanol (98:2, v/v) plus 0.1% diethylamine as the isocratic mobile phase, at a flow rate of 1.2 ml/min.",New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ml] / [min],1.2,192825,DB00370,Mirtazapine
less,15315787,total analysis time,The total analysis time was less than 12 min per sample.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),-1·min,12,192826,DB00370,Mirtazapine
,15315787,recoveries,The recoveries of (+)-(S)- and (-)-(R)-mirtazapine were in the 88-111% range with a linear response over the 6.25-625 ng/ml concentration range for both enantiomers.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),%,88-111,192827,DB00370,Mirtazapine
,15315787,quantification limit (LOQ),The quantification limit (LOQ) was 5 ng/ml.,New method for the chiral evaluation of mirtazapine in human plasma by liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315787/),[ng] / [ml],5,192828,DB00370,Mirtazapine
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB00370,Mirtazapine
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB00370,Mirtazapine
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB00370,Mirtazapine
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB00370,Mirtazapine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB00370,Mirtazapine
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB00370,Mirtazapine
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],1516.62,195558,DB00370,Mirtazapine
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],1613.63,195559,DB00370,Mirtazapine
,19429471,dose/weight adjusted AUC(0-infinity),"Attending to the theoretical figures provided by the model, mean (95% CI) dose/weight adjusted AUC(0-infinity) (ng h/ml)/(mg/kg) is 1516.62 (1411.27-1628.22) in EM/UM, 1613.63 (1482.14-1758.55) in IM and 2049.28 (1779.78-2357.24) in PM.","Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),[h·ml·ng] / [kg·mg],2049.28,195560,DB00370,Mirtazapine
,19429471,AUC(0-infinity),Females show a lower dose/weight adjusted AUC(0-infinity): 1594.39 (1477.70-1720.28) vs. 1837.65 (1694.67-1992.70).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,1594.39,195561,DB00370,Mirtazapine
,19429471,AUC(0-infinity),Females show a lower dose/weight adjusted AUC(0-infinity): 1594.39 (1477.70-1720.28) vs. 1837.65 (1694.67-1992.70).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,1837.65,195562,DB00370,Mirtazapine
,19429471,dose,On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,38.33,195563,DB00370,Mirtazapine
,19429471,C(max),On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,38.33,195564,DB00370,Mirtazapine
,19429471,C(max),On the contrary dose/weight adjusted C(max) is higher in females than in males: 38.33 (34.79-42.28) vs. 32.66 (29.44-36.21).,"Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429471/),,32.66,195565,DB00370,Mirtazapine
,21985134,half-life,Mean half-life ± SD was 15.2 ± 4.2 hours (CKD) and 12.1 ± 1.1 hours (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),h,15.2,203462,DB00370,Mirtazapine
,21985134,half-life,Mean half-life ± SD was 15.2 ± 4.2 hours (CKD) and 12.1 ± 1.1 hours (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),h,12.1,203463,DB00370,Mirtazapine
,21985134,area under the curve (AUC),Mean area under the curve (AUC) ± SD was 770.6 ± 225.5 ng/mL•hr (CKD) and 555.5 ± 175.4 ng/mL•hr (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[ng] / [h·ml],770.6,203464,DB00370,Mirtazapine
,21985134,area under the curve (AUC),Mean area under the curve (AUC) ± SD was 770.6 ± 225.5 ng/mL•hr (CKD) and 555.5 ± 175.4 ng/mL•hr (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[ng] / [h·ml],555.5,203465,DB00370,Mirtazapine
,21985134,CL/F,Mean CL/F ± SD was 0.6 ± 0.1 L/hr/kg (CKD) and 0.8 ± 0.16 L/hr/kg (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[l] / [h·kg],0.6,203466,DB00370,Mirtazapine
,21985134,CL/F,Mean CL/F ± SD was 0.6 ± 0.1 L/hr/kg (CKD) and 0.8 ± 0.16 L/hr/kg (AMC).,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),[l] / [h·kg],0.8,203467,DB00370,Mirtazapine
,21985134,accumulation factor,Calculated accumulation factor for 48-hour dosing in CKD cats was 1.15.,The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985134/),,1.15,203468,DB00370,Mirtazapine
,32238137,C/D MIR level,Combined genotype analyses also revealed that individuals with CYP2D6*1/*1 - POR*28/*28 genotype have a statistically lower C/D MIR level (0.95 ng/ml/dose) when compared with individuals with CYP2D6*1/*1 - POR*1/*1 genotype (1.52 ng/ml/dose).,The Association of CYP2D6*4 and POR*28 Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238137/),[ng] / [dose·ml],0.95,207395,DB00370,Mirtazapine
,32238137,C/D MIR level,Combined genotype analyses also revealed that individuals with CYP2D6*1/*1 - POR*28/*28 genotype have a statistically lower C/D MIR level (0.95 ng/ml/dose) when compared with individuals with CYP2D6*1/*1 - POR*1/*1 genotype (1.52 ng/ml/dose).,The Association of CYP2D6*4 and POR*28 Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32238137/),[ng] / [dose·ml],1.52,207396,DB00370,Mirtazapine
,25078020,concentration,Median mirtazapine concentration was 43.6 μg/L (164.37 nmol) at a daily dosage range of 7.5-60 mg.,Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [l],43.6,215752,DB00370,Mirtazapine
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[μg] / [d·l·mg],1.48,215753,DB00370,Mirtazapine
,25078020,concentration-to-dose (C/D) ratio,"Mean concentration-to-dose (C/D) ratio was 1.48 μg/L/mg/day (5.58 nmol/mg/day), which was higher than that in a previous study in Caucasian subjects.",Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25078020/),[nM] / [d·mg],5.58,215754,DB00370,Mirtazapine
,14726991,initial clearance from blood to tissue (K1),"[N-methyl-11C]Mirtazapine entered the brain readily, with initial clearance from blood to tissue (K1) ranging from 0.31 ml/ml/min in amygdala to 0.54 ml/ml/min in thalamus.",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),[ml] / [min·ml],0.31,230710,DB00370,Mirtazapine
,14726991,initial clearance from blood to tissue (K1),"[N-methyl-11C]Mirtazapine entered the brain readily, with initial clearance from blood to tissue (K1) ranging from 0.31 ml/ml/min in amygdala to 0.54 ml/ml/min in thalamus.",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),[ml] / [min·ml],0.54,230711,DB00370,Mirtazapine
,14726991,clearance,The clearance of [N-methyl-11C]mirtazapine from the tissue compartment (k2') ranged from a low of 0.03 min(-1) in amygdala to a high of 0.06-0.07 min(-1) in thalamus and cerebellum.,[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),1/[min],0.03,230712,DB00370,Mirtazapine
,14726991,clearance,The clearance of [N-methyl-11C]mirtazapine from the tissue compartment (k2') ranged from a low of 0.03 min(-1) in amygdala to a high of 0.06-0.07 min(-1) in thalamus and cerebellum.,[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),1/[min],0.06-0.07,230713,DB00370,Mirtazapine
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,11,230714,DB00370,Mirtazapine
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,6.7,230715,DB00370,Mirtazapine
,14726991,volume of distribution (Ve'),"The volume of distribution (Ve') of [N-methyl-11C]mirtazapine was markedly greater in hippocampus and amygdala (11.3-12.0) than in cerebellum (6.7), with intermediate levels in the thalamus (9.4).",[N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14726991/),,9.4,230716,DB00370,Mirtazapine
,22877221,turnaround time,"The approach allows for the investigation of a set of six compounds simultaneously, with a turnaround time of 1 week or less.",A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22877221/),week,1,231407,DB00370,Mirtazapine
,21652240,half-life,The mean half-life of MRT was 6.17 h with a clearance of 1193 mL/h/kg.,Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21652240/),h,6.17,249192,DB00370,Mirtazapine
,21652240,clearance,The mean half-life of MRT was 6.17 h with a clearance of 1193 mL/h/kg.,Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21652240/),[ml] / [h·kg],1193,249193,DB00370,Mirtazapine
